Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Cilostazol para la prevención del accidente cerebrovascular recurrente en África (CLARITY-Africa)

10 de noviembre de 2026 actualizado por: Bruce Ovbiagele, Northern California Institute of Research and Education

Global estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke. With an estimated 1.4 million stroke survivors, outcomes of stroke in SSA are abysmal with 1-month case fatality at 30% and 3-year mortality rate of 84%. Stroke survivors in Africa are at an inordinately high (and worsening) risk of adverse outcomes including recurrent stroke and cardiac events over the medium- to longterm. Given the paucity of resources in the region, testing of therapies, which are potentially highly clinically efficacious and cost-effective, while developing local stroke research capacity and contributing to the global secondary stroke prevention evidence base, is urgently needed. Cilostazol, a phosphodiesterase 3 inhibitor, has shown promising efficacy and safety mainly among an Asian population by cutting risk of major adverse cardiovascular events including stroke, in half, when added to aspirin or clopidogrel (8% vs. 4%, HR 0.52, 95% CI 0.35-0.77), with no increased risk in bleeding or serious adverse events. Cilostazol's potentially strong efficacy, presumed pleiotropic effects, and relatively low cost, make it a highly appealing agent for use in stroke-prone, low-resource settings. Therefore, the overall objective of the CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-AFRICA) study is to deploy a hybrid study design to demonstrate the efficacy and safety of cilostazol twice daily in reducing MACE over 24 months vs. placebo among 1100 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, CLARITY-AFRICA also seeks to develop an implementation strategy for routine integration and policy adoption of cilostazol for post-stroke cardiovascular risk reduction in an under-resourced system. Given its compelling efficacy among a predominantly Asian population, the National Institute of Neurological Disorders and Stroke (NINDS) is poised to fund a US-based clinical trial to assess the longer-term efficacy and safety of cilostazol in a study titled CiLostAzol for pReventIon of recurrent sTroke (CLARITY). The investigators are also aware that European and Australian funding agencies are considering stroke trials of cilostazol. A concurrently executed CLARITYAfrica trial would allow recruitment of a historically underrepresented and high-risk group (Africans), test a therapy that if efficacious could be affordable for broader regional implementation, permit transcontinental mentorship/collaborations, and leverage NINDS impending investment. CLARITY-AFRICA will assess implementation outcomes such as adoption, acceptability, cost, pertinent to uptake of cilostazol in Ghana to inform policy. Regardless of its outcome, findings from CLARITYAFRICA will contribute meaningful information from the African perspective to inform the formulation of guidelines for global adoption of cilostazol into routine care for secondary CVD risk prevention by international bodies such as the World Health Organization. This application will focus on the first 2 aims of CLARITY-AFRICA to conduct the trial and assess secondary outcomes.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

1100

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Bruce Ovbiagele, M.D., MSc, MAS, MBA
  • Número de teléfono: 415-750-2047
  • Correo electrónico: bruce.ovbiagele@va.gov

Ubicaciones de estudio

      • Kumasi, Ghana
        • Kwame Nkrumah University of Science & Technology
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

30 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Above the age of 30 years; male or female (sex is a biological variable of interest)
  2. Ischemic stroke or high-risk TIA (ABCD2 score >= 6) diagnosis no greater than six months before enrollment. Ischemic strokes including lacunar, large vessel atherosclerotic, embolic stroke of undetermined source subtypes are eligible (Ischemic stroke or TIA should be confirmed by either with a cranial CT or MRI within 10 days of symptom onset)
  3. Aspirin or clopidogrel monotherapy
  4. Subjects with stroke may present with two or more of the following additional conditions: age ≥65 years, documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension >140/90mmHg or previous treatment with anti-hypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction
  5. Legally competent to sign informed consent or have a LARs who is able to provide consent for them
  6. In the opinion of the treating physician, patient is medically stable, capable of participating in a randomized trial, and willing and able to attend follow-up.
  7. Able to do labs at all study intervals (7 visits total)

Exclusion Criteria:

  1. Unable to provide a valid informed consent
  2. Contraindications to cilostazol (namely (i) hypersensitivity, (ii) active pathologic bleeding, e.g. bleeding peptic ulcer, intracranial bleeding due to reversible platelet aggregation, (iii) congestive cardiac failure.)
  3. Hemorrhagic stroke survivor within the last 2 years
  4. Use of an anticoagulant medication or indication for use of an anticoagulant (e.g. atrial fibrillation)
  5. On dual antiplatelet therapy (patients are eligible after completion of a course of dual antiplatelet therapy)
  6. Modified Rankin Scale 5
  7. Thrombocytopenia (platelet count <1000,000)
  8. Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C)
  9. Congestive heart failure, defined as NYHA Class III or above (marked limitation of physical activity)
  10. Nursing/pregnant mothers

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cilostazol Experimental Arm

Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.

Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.

Sin intervención: Control Arm

Standard of post-stroke care

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Porcentaje de los participantes con mayores eventos cardiovasculares adversos
Periodo de tiempo: 36 meses
36 meses

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Porcentaje de participantes con hemorragia mayor y menor
Periodo de tiempo: 24 meses
24 meses
Porcentaje de los participantes con accidente cerebrovascular recurrente (isquémico o hemorrágico)
Periodo de tiempo: 24 meses
24 meses
Porcentaje de participantes con muertes cardiovasculares
Periodo de tiempo: 24 meses
24 meses
Porcentaje de los participantes con todos causa mortalidad
Periodo de tiempo: 24 meses
24 meses
Neuro-QoL (Quality of Life)
Periodo de tiempo: 24 months

12 monthly

Neuro-QoL uses T-scores, which are standardized scores:

Mean (average) = 50 Standard deviation = 10

Interpreting T-scores:

Scores 0.5 - 1.0 SD worse than the mean = mild symptoms/impairment Scores 1.0 - 2.0 SD worse than the mean = moderate symptoms/impairment Scores 2.0 SD or more worse than the mean = severe symptoms/impairment

For negative domains (e.g. anxiety, depression, fatigue):

Higher = Worse

We will compare mean Neuro-QoL scores between the two arms of the study at study completion as well as proportions with mild, moderate and severe impairment.

24 months
Exploratory outcomes Montreal Cognitive Assessment
Periodo de tiempo: 24 months

6 monthly. Comparison of Slopes of MOCA scores over 24 months. Range of scores on MOCA: 0 to 30.

MOCA screening tool is used to detect mild cognitive impairment and early signs of dementia. It evaluates several cognitive domains, including:

Memory Attention Language Visuospatial skills Executive function Orientation

A score of 26 or above is considered normal. Scores below 26 may suggest cognitive impairment, depending on education level and clinical context.

24 months
Quality of Life (EQ-5D Questionnaire)
Periodo de tiempo: 24 months

The EQ-5D is a health-related quality of life questionnaire with two parts:

Descriptive system: Assesses 5 dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated on 3 or 5 levels (from no problems to extreme problems).

Visual Analog Scale (VAS): Rates overall health from 0 (worst) to 100 (best).

Scoring:

The 5-digit health state is converted into a summary index score (range: <0 to 1), with 1 = full health.

The VAS reflects the person's self-rated health.

We will compare scores between the two arms at study completion.

24 months
Modified Rankin Score
Periodo de tiempo: 24 months

The Modified Rankin Scale (mRS) measures the degree of disability or dependence in daily activities after a stroke or other neurological injury.

Scoring:

0 - No symptoms

  1. - No significant disability; able to carry out all usual activities
  2. - Slight disability; unable to do all previous activities but able to look after own affairs
  3. - Moderate disability; needs some help but can walk unassisted
  4. - Moderately severe disability; unable to walk or attend to bodily needs without help
  5. - Severe disability; bedridden, incontinent, requires constant care
  6. - Dead
24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de enero de 2027

Finalización primaria (Estimado)

31 de julio de 2029

Finalización del estudio (Estimado)

31 de agosto de 2029

Fechas de registro del estudio

Enviado por primera vez

17 de marzo de 2025

Primero enviado que cumplió con los criterios de control de calidad

2 de abril de 2025

Publicado por primera vez (Actual)

9 de abril de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant level data will be aggregated and maintained as de-identified to protect PHI

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir